Javier Ruiz Martínez

Javier Ruiz Martínez

Auto-generated profile, based on publicly available information

Javier Ruiz Martínez

Department of Neurology, Donostia University Hospital, Biogipuzkoa Health Research Institute, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), San Sebastián ES 20014, Spain

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2018 in Endocrine
Verified
Journal Article
Closed access
PDF file
GEGema Esteban-Bueno
Gema Esteban-Bueno
DRDyanne Ruiz-Castañeda
Dyanne Ruiz-Castañeda
JMJavier Ruiz Martínez
Javier Ruiz Martínez
MMManuel Romero Muñoz
Manuel Romero Muñoz
PAPedro Carrillo Alascio
Pedro Carrillo Alascio

1 April 2025 in Neurology Genetics
Verified
Journal Article
Open access
SCShihan Chen
Shihan Chen
CACatherine Ashton
Catherine Ashton
RSRawan Sakalla
Rawan Sakalla
GCGuillemette Clement
Guillemette Clement
SPSophie Planel
Sophie Planel
RPRoberta La Piana
Roberta La Piana
GAA-FGF14 ataxia (SCA27B) is a recently reported late-onset ataxia caused by a GAA repeat expansion in intron 1 of the FGF14 gene. After the clinical observation of superior cerebellar peduncle (SCP) involvement in some affected patients, we sought to verify the prevalence of this finding in our cohort and 4 additional independent cohorts of patients with SCA27B. We performed a retrospective review of the brain MRI scans of a total of 87 patients (median age at MRI 69 years; range 28-88 years) from different independent cohorts to assess the presence of SCP involvement, defined as abnormally high T2 signal along the SCP tract. We observed SCP involvement in 52 patients (52/87; 59.8%) from all the cohorts combined. The finding was replicated at rates ranging from 50% to 62.8% in the cohorts taken separately. SCP involvement in SCA27B is frequent. Its detection may facilitate the diagnostic process of patients with SCA27B.

7 April 2021 in Journal of Parkinson’s Disease
Verified
Journal Article
Open access
PDF file
DGDiego Santos García
Diego Santos García
TFTeresa de Deus Fonticoba
Teresa de Deus Fonticoba
CBCarlos Cores Bartolomé
Carlos Cores Bartolomé
ECEster Suárez Castro
Ester Suárez Castro
JHJorge Hernández-Vara
Jorge Hernández-Vara
CGCOPPADIS Study Group
COPPADIS Study Group
Background: There is a need for identifying risk factors for hospitalization in Parkinson’s disease (PD) and also interventions to reduce acute hospital admission. Objective: To analyze the frequency, causes, and predictors of acute hospitalization (AH) in PD patients from a Spanish cohort. Methods: PD patients recruited from 35 centers of Spain from the COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015) cohort from January 2016 to November 2017, were included in the study. In order to identify predictors of AH, Kaplan-Meier estimates of factors considered as potential predictors were obtained and Cox regression performed on time to hospital encounter 1-year after the baseline visit. Results: Thirty-five out of 605 (5.8%) PD patients (62.5±8.9 years old; 59.8% males) presented an AH during the 1-year follow-up after the baseline visit. Traumatic falls represented the most frequent cause of admission, being 23.7% of all acute hospitalizations. To suffer from motor fluctuations (HR [hazard ratio] 2.461; 95% CI, 1.065–5.678; p = 0.035), a very severe non-motor symptoms burden (HR [hazard ratio] 2.828; 95% CI, 1.319–6.063; p = 0.008), falls (HR 3.966; 95% CI 1.757–8.470; p = 0.001), and dysphagia (HR 2.356; 95% CI 1.124–4.941; p = 0.023) was associated with AH after adjustment to age, gender, disease duration, levodopa equivalent daily dose, total number of non-antiparkinsonian drugs, and UPDRS-IIIOFF. Of the previous variables, only falls (HR 2.998; 95% CI 1.080–8.322; p = 0.035) was an independent predictor of AH. Conclusion: Falls is an independent predictor of AH in PD patients.

31 January 2025 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
AMAne Murueta-Goyena
Ane Murueta-Goyena
STSara Teijeira-Portas
Sara Teijeira-Portas
EMElisa Blanco Martín
Elisa Blanco Martín
RVRaquel Vázquez-Picón
Raquel Vázquez-Picón
BBBlanca Ruiz Bajo
Blanca Ruiz Bajo
IGIñigo Gabilondo
Iñigo Gabilondo
Parkinson’s disease (PD) is a neurodegenerative disorder primarily characterized by motor symptoms, with emerging evidence suggesting retinal pathology, particularly in the ganglion cell-inner plexiform layer (GCIPL), detectable via optical coherence tomography (OCT). This study aimed to characterize early retinal dynamics in PD using OCT. We conducted a prospective one-year longitudinal multicenter study involving 53 early-stage PD patients with a disease duration of 5 years or less and 52 controls. The participants underwent retinal spectral-domain OCT, primary visual function and cognitive examinations. We examined baseline retinal measures and short-term longitudinal differences between groups via linear mixed effects models. In PD patients, the baseline GCIPL thickness in central regions was increased by up to 4 μm, and the rate of thinning in the parafoveal GCIPL was − 0.61 [0.29] µm/year faster over a one-year follow-up period than in controls in the 2- to 3-mm ring (p = 0.039). In PD patients, greater central GCIPL thickness was associated with poorer contrast sensitivity and reduced performance on the Farnsworth D15 color vision test. It also predicted subsequent thinning in both the GCIPL (2- to 3-mm ring) and the inner nuclear layer (2- to 5-mm rings). However, this increased thickness was not linked to prevalent or progressive motor or cognitive manifestations. In conclusion, this study provides the first detailed topographical description of early retinal dynamics in PD patients, revealing increased central GCIPL thickness and accelerated parafoveal GCIPL thinning in PD. However, the macular region shows complex and variable dynamics among PD patients, but these changes precede detectable progression in clinical scales.

19 July 2024 in Movement Disorders
Verified
Journal Article
Closed access
IAInes Albajar
Ines Albajar
PIPablo Iruzubieta
Pablo Iruzubieta
MBMyriam Barandiaran
Myriam Barandiaran
PAPatricia Alves
Patricia Alves
APAurora Pujol
Aurora Pujol
AAAdolfo López de Munain Arregui
Adolfo López de Munain Arregui

26 June 2026 in medRxiv
Verified
Preprint
Open access
ACAnthea Cheung
Anthea Cheung
NPNeringa Pratuseviciute
Neringa Pratuseviciute
KBKirsten Black
Kirsten Black
PLPaweł Lis
Paweł Lis
TPToan Phung
Toan Phung
ESEsther Sammler
Esther Sammler
Pathogenic variants in leucine-rich repeat kinase 2 ( LRRK2 ) 1 are among the most frequent monogenic causes of Parkinson’s disease (PD) 2 and act through a gain-of-function mechanism of increased kinase activity. LRRK2 -targeted therapies are in clinical development, but interpretation of the rapidly expanding catalogue of rare LRRK2 variants remains a barrier to translation. Here, we present functionally annotated data on >350 LRRK2 coding variants using a standardized cellular assay with Rab10 phosphorylation as a readout of kinase activity and integrated these data with curated genetic and clinical annotations from the Movement Disorders Society Genetic Mutation Database (MDSGene). Variants differed in activation magnitude, ranging from modest increases (e.g., p.G2019S) to strongly activating substitutions such as p.Y1699C or p.L1795F. Activating variants occurred across the full length of LRRK2, although the largest effects clustered within the ROC–COR regulatory hub, where structural analysis identified subdomains forming an allosteric scaffold controlling kinase output. All known/established pathogenic variants showed increased activity, whereas benign and likely benign variants remained within the wild-type range. Functional effect sizes correlated with pathway activation in patient-derived immune cells, altogether providing a framework for ACMG-based variant interpretation in which kinase activation can support PS3 functional evidence for reclassification of variants.